Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 1

Conditions

Atherosclerosis

Treatments

Drug: SB-480848 (Darapladib)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00622830

LPL110736

Details and patient eligibility

About

This study is being conducted to provide safety, tolerability, PK and PD data in repeat dosing that will allow further studies with darapladib in Japanese patients

Enrollment

18 estimated patients

Sex

Male

Ages

20 to 64 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy Japanese adult males between 20 and 64 yeas of age, inclusive.
Healthy subjects are defined as individuals who are free from clinically significant disease as determined by their medical history, physical examination, clinical laboratory examinations, vital sign, 12-lead ECG, immunology tests and urinary drug screen test.
Bodyweight >50 kg and body mass index (BMI) between 18.5 and 25.0 at screening.
Subjects must be capable of providing written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Baseline QTc interval <450 msec.
Non-smoker or ex-smoker having ceased smoking for at least 6 months.
Clinical laboratory examination (AST, ALT, ALP and GGT) at screening are within the normal range.
The subject is able to attend all visits and complete the study.

Exclusion criteria

Any clinically relevant abnormality identified on the screening physical examination, vital sign measurement, 12-lead ECG recording and/or clinical laboratory examination that is deemed by the principal investigator and/or medical monitor to make the subject ineligible for inclusion because of a safety concern.
History of regular alcohol consumption exceeding, on average, 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 350 mL of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits) within 6 months of screening.
Positive for urine drug at screening.
Positive for syphilis, HIV antibody, Hepatitis B surface antigen, Hepatitis C antibody or HTLV-1 antibody at screening.
Use of prescription or no-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.
Consumption of grapefruit juice or food within 7 days prior to the first dose of study medication.
A history of cholecystectomy or biliary tract disease including a history of liver disease with elevated liver function tests of known or unknown etiology.
Donation of blood in excess of 400mL within 4 months or 200mL within 1 months prior to at screening.
History of drug abuse, or current conditions of drug abuse or alcoholism.
Participation in a clinical study or post-marketing study with an investigational or a non-investigational product or device within 4 months of preceding the first dose of study medication.
Participation in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational product or device.
History of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses.
The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen allergy without current symptoms.
History of sensitivity to heparin or heparin-induced thrombocytopenia.